Table of Contents:

1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of the Study
3.3 List of Assumptions
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Increasing prevalence of thyroid diseases
5.2.2 Rising awareness of thyroid
5.2.3 Favorable reimbursement and funding policies
5.2.4 Drivers Impact Analysis
5.3 Restraint
5.3.1 High cost of treatment procedures such as radioactive iodine (RAI) therapy
5.3.2 Side-effects related to available therapeutics
5.3.3 Restraints Impact Analysis
5.4 Opportunity
5.4.1 Emerging markets of Asia-Pacific
5.5 Macroeconomic Indicators
6 Market Factor Analysis
6.1 Porter's Five Forces Model
6.1.1 Threat of New Entrants
6.1.2 Bargaining Power of Suppliers
6.1.3 Threat of Substitutes
6.1.4 Bargaining Power of Buyers
6.1.5 Intensity of Rivalry
7 Global Thyroid Disorder Market, by Type
7.1 Overview
7.1.1 Introduction
7.1.2 Hypothyroidism
7.1.3 Hyperthyroidism
8 Global Thyroid Disorder Market, by Treatment
8.1 Overview
8.1.1 Introduction
8.1.2 Medications
8.1.3 Radioactive Iodine Therapy
8.1.4 Surgery
9 Global Thyroid Disorder Market, by Route of Administration
9.1 Overview
9.1.1 Oral
9.1.2 Intravenous
10 Global Thyroid Disorder Market, by End User
10.1 Overview
10.1.1 Hospitals
10.1.2 Clinics
11 Global Thyroid Disorder Market, by Region
11.1 Overview
11.2 Americas
11.2.1 North America
11.2.1.1 US
11.2.1.2 Canada
11.2.2 South America
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 UK
11.3.1.4 Italy
11.3.1.5 Spain
11.3.1.6 Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia-Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Republic of Korea
11.4.5 Australia
11.4.6 Rest of Asia-Pacific
11.5 Middle East & Africa
11.5.1 Middle East
11.5.2 Africa
12 Competitive Landscape
12.1 Company Market Share Analysis
12.1.1 Introduction
13 Company Profiles
13.1 Pfizer Inc
13.1.1 Company Overview
13.1.2 Financial Overview
13.1.3 Products/Services Offered
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.1.6 Key Strategy
13.2 Allergan Inc.
13.2.1 Company Overview
13.2.2 Financial Overview
13.2.3 Products/Services Offered
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.2.6 Key strategy
13.3 AbbVie Inc.
13.3.1 Company Overview
13.3.2 Financial Overview
Source: Annual Report, Press Releases, MRFR Analysis 104
13.3.3 Products/Services Offering
13.3.4 Key Developments
13.3.5 SWOT Analysis
13.3.6 Key Strategy
13.4 Merck KGaA
13.4.1 Company Overview
13.4.2 Financial Overview
Source: Annual Report, Press Releases, MRFR Analysis 106
13.4.3 Products/Services Offering
13.4.4 Key Developments
13.4.5 SWOT Analysis
13.4.6 Key Strategy
13.5 RLC Labs
13.5.1 Company Overview
13.5.2 Financial Overview
13.5.3 Products/Services Offered
13.5.4 SWOT Analysis
13.5.5 Key Developments
13.5.6 Key strategy
13.6 Abbott Laboratories
13.6.1 Company Overview
13.6.2 Financial Overview
13.6.3 Products/Services Offered
13.6.4 Key Developments
13.6.5 SWOT Analysis
13.6.6 Key Strategy
13.7 GlaxoSmithKline Plc
13.7.1 Company Overview
13.7.2 Financial Overview
13.7.3 Products/Services Offered
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.7.6 Key Strategy
13.8 Mylan
13.8.1 Company Overview
13.8.2 Financial Overview
13.8.3 Products/Services Offered
13.8.4 Key Developments
13.8.5 SWOT Analysis
13.8.6 Key Strategy
14 Appendix
14.1 Discussion Blue Print